NCT04786444已完成3 期
A Randomized, Double-Blinded Phase 3 Study to Demonstrate Lot-to-Lot Consistency of Three Lots of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Adults Aged 18 to 45 Years
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 409
- 试验地点
- 24
- 主要终点
- Geometric Mean Titer (GMT) of CHIKV-specific Neutralizing Antibodies as Determined by Microneutralization (μPRNT) Assay in Subjects Who Tested Negative for CHIKV Antibodies at Baseline
研究概览
简要总结
This was a prospective, randomized, double-blinded, multicenter Phase 3 clinical study investigating three Lots of VLA1553 at the final dose. Overall 409 healthy subjects aged 18 to 45 years were randomized into the study.
详细描述
This was a prospective, randomized, double-blinded, multicenter Phase 3 clinical study investigating three Lots of VLA1553. Overall 409 healthy subjects aged 18 to 45 years were randomized into the study, approximately136 subjects per VLA1553 Lot. Subjects were block-randomized in a 1:1:1 ratio into the three study arms to receive one of three Lots of VLA1553 as a single i.m. vaccination. The primary objective was to demonstrate Lot-to-Lot manufacturing consistency of VLA1553 28 days following the single vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •18 to 45 years of age on the Day of screening
- •Able to provide informed consent
- •Generally healthy as determined by the Investigator's clinical judgement based on medical history, physical examination and screening laboratory tests
- •For women of childbearing potential:
- •practiced an adequate method of contraception during 30 days before screening
- •negative serum or urine pregnancy test at screening or vaccination, respectively
- •agreed to employ adequate birth control measures for the first three months post-vaccination.
排除标准
- •CHIKV infection in the past (self-reported), including suspected CHIKV infection; was taking medication or other treatment for unresolved symptoms attributed to a previous CHIKV infection; or had participated in a clinical study involving an investigational CHIKV vaccine
- •Acute or recent infection (and not symptom-free in the week prior to screening)
- •Tested positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV);
- •Received another live virus vaccine within 28 days or inactivated vaccine within 14 days prior to vaccination in this study or plans to receive a vaccine within 28 days or 14 days after vaccination, respectively
- •Abnormal findings in any required study investigations (including medical history, physical examination, and clinical laboratory) considered clinically relevant by the Investigator which pose a risk for participation in the study
- •Medical history of or currently had acute or progressive, unstable or uncontrolled clinical conditions that posed a risk for participation in the study
- •History of immune-mediated or clinically relevant arthritis / arthralgia
- •History of malignancy in the past 5 years other than squamous cell or basal cell skin cancer. If there had been surgical excision or treatment more than 5 years ago that was considered to have achieved a cure, the subject could be enrolled.
- •Known or suspected defect of the immune system, such as subjects with congenital or acquired immunodeficiency, including infection with HIV, status post organ transplantation or immuno-suppressive therapy within 4 weeks prior to vaccination.
- •History of any vaccine related contraindicating event (e.g., anaphylaxis, allergy to components of the candidate vaccine, other known contraindications)
- •Clinical conditions representing a contraindication to intramuscular vaccination and blood draws
- •Pregnant, had plans to become pregnant during the first three months post-vaccination or lactating at the time of enrollment
- •Donation of blood, blood fractions or plasma within 30 days or received blood-derived products (e.g. plasma) within 90 days prior to vaccination in this study or planned to donate blood or use blood products until Day 180 of the study
- •Rash, dermatological condition or tattoos that would, in the opinion of the Investigator, interfere with injection site reaction rating
- •Known or suspected problem with alcohol or drug abuse as determined by the Investigator
- •Any condition that, in the opinion of the Investigator, could compromise the subjects well-being, could interfere with evaluation of study endpoints, or could limit the subject's ability to complete the study;
- •Committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities)
- •Participation in another clinical study involving an investigational medicinal product (IMP) or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving an IMP, or device during the course of this study
- •Member of the team conducting the study or in a dependent relationship with one of the study team members. Dependent relationships include close relatives (i.e., children, partner/spouse, siblings, parents) as well as employees of the Investigator or site personnel conducting the study.
结局指标
主要结局
Geometric Mean Titer (GMT) of CHIKV-specific Neutralizing Antibodies as Determined by Microneutralization (μPRNT) Assay in Subjects Who Tested Negative for CHIKV Antibodies at Baseline
时间窗: On Day 29 after single vaccination
次要结局
- Severity of Solicited Injection Site(10 days post vaccination)
- Fold Increase of CHIKV-specific Neutralizing Antibody Titers Compared to Baseline(on Day 8, 29, 85 and Month 6)
- Immune Response as Measured by CHIKV-specific Neutralizing Antibody Titers(on Day 8, 85 and Month 6)
- Frequency of Any Adverse Event of Special Interest (AESI)(Within 2 to 21 Days Post-vaccination)
- Proportion of Subjects Reaching an at Least 4-fold, 8-fold, 16-fold or 64-fold Increase in CHIKV-specific Neutralizing Antibody Titer Compared to Baseline(up to Month 6)
- Frequency of Solicited Injection Site(10 days post vaccination)
- Frequency of Any Serious Adverse Event (SAE) During the Entire Study Period(up to Month 6)
- Proportion of Subjects With Seroconversion(on Day 29, Day 85 and Month 6)
- Proportion of Subjects With Seroprotective Levels for Baseline Negative Subjects(on Day 8, 29, 85 and Month 6)
- Frequency of Solicited Systemic Reactions(10 days post vaccination)
- Severity of Unsolicited Adverse Events (AEs) Within 28 Days Post-vaccination(up to Day 29)
- Severity of Any Adverse Event During the Entire Study Period(up to Month 6)
- Frequency of Any Adverse Event During the Entire Study Period(up to Month 6)
- Severity of Solicited Systemic Reactions(10 days post vaccination)
- Frequency of Unsolicited Adverse Events (AEs) Within 28 Days Post-vaccination(up to Day 29)
- Severity of Any Adverse Event of Special Interest (AESI)(within 2 to 21 days post-vaccination)
研究者
研究点 (24)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal InfectionsComplicated Intra-abdominal InfectionsComplicated AppendicitisNCT02784704Tetraphase Pharmaceuticals, Inc.500
已完成
3 期
Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal InfectionsComplicated Intra-abdominal InfectionsNCT01844856Tetraphase Pharmaceuticals, Inc.541
终止
3 期
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine TumoursNeuroendocrine Tumors in LungNCT02683941Ipsen77
已完成
3 期
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)Clostridium Difficile Infection (CDI)NCT03244644Rebiotix Inc.320
已完成
3 期
Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract InfectionscUTINCT01978938Tetraphase Pharmaceuticals, Inc.908